Reprint of: Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease - Resemblance to the effect of amphetamine drugs of abuse

Free Radical Biology and Medicine

Volumn 62, Issue , 2013, Pages 186-201

  Perfeito, Rita ^a   Cunha Oliveira, Teresa ^a   Rego, Ana Cristina ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Amphetamines; Dopamine; Free radicals; Mitochondrial dysfunction; Oxidative stress; Parkinson disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; AMPHETAMINE; DJ 1 PROTEIN; DOPAMINE; LEUCINE RICH REPEAT KINASE 2; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN INDUCED PUTATIVE KINASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; UNCLASSIFIED DRUG;

AUTOSOMAL DOMINANT INHERITANCE; CLINICAL FEATURE; DEGENERATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ABUSE; ENVIRONMENTAL FACTOR; EXCITOTOXICITY; FAMILIAL DISEASE; GENE MUTATION; HUMAN; LONG TERM EXPOSURE; MORPHOLOGY; NERVE DEGENERATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; RESPIRATORY CHAIN; REVIEW; RISK FACTOR;

EID: 84884889978     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2013.05.042     Document Type: Review

References (318)

1. de Rijk, M. C.; Launer, L. J.; Berger, K.; Breteler, M. M.; Dartigues, J. F.; Baldereschi, M., et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S21-S23; 2000. (Pubitemid 30390601)
2. Bekris, L. M.; Mata, I. F.; Zabetian, C. P. The genetics of Parkinson disease. J. Geriatr. Psychiatry Neurol. 23: 228-242; 2010.
3. Sellbach, A. N.; Boyle, R. S.; Silburn, P. A.; Mellick, G. D. Parkinson's disease and family history. Parkinsonism Relat. Disord. 12: 399-409; 2006. (Pubitemid 44430174)
4. Farrer, M. J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7: 306-318; 2006.
5. de Lau, L. M.; Breteler, M. M. Epidemiology of Parkinson's disease. Lancet Neurol. 5: 525-535; 2006. (Pubitemid 44262284)
6. Mounsey, R. B.; Teismann, P. Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. Parkinsons Dis 617472: 2010; 2011.
7. Schapira, A. H. Etiology and pathogenesis of Parkinson disease. Neurol. Clin. 27: 583-603; 2009. v.
8. Schapira, A. H.; Cooper, J. M.; Dexter, D.; Clark, J. B.; Jenner, P.; Marsden, C. D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54: 823-827; 1990.
9. Schapira, A. H.; Cooper, J. M.; Dexter, D.; Jenner, P.; Clark, J. B.; Marsden, C. D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1: 1269; 1989. (Pubitemid 19140359)
10. Dexter, D. T.; Jenner, P.; Schapira, A. H.; Marsden, C. D. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol 32(Suppl):S94-100; 1992.
11. Owen, A. D.; Schapira, A. H.; Jenner, P.; Marsden, C. D. Oxidative stress and Parkinson's disease. Ann. N. Y. Acad. Sci. 786: 217-223; 1996. (Pubitemid 26273166)
12. Mann, V. M.; Cooper, J. M.; Schapira, A. H. Quantitation of a mitochondrial DNA deletion in Parkinson's disease. FEBS Lett 299: 218-222; 1992.
13. Schapira, A. H. Oxidative stress in Parkinson's disease. Neuropathol. Appl. Neurobiol. 21: 3-9; 1995.
14. Gu, M.; Owen, A. D.; Toffa, S. E.; Cooper, J. M.; Dexter, D. T.; Jenner, P., et al. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J. Neurol. Sci. 158: 24-29; 1998. (Pubitemid 28277530)
15. Schapira, A. H. Challenges to the development of disease-modifying therapies in Parkinson's disease. Eur. J. Neurol 18(Suppl. 1): 16-21; 2011.
16. Rego, A. C.; Oliveira, C. R. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem. Res 28: 1563-1574; 2003. (Pubitemid 37193539)
17. Dickson, D. W.; Braak, H.; Duda, J. E.; Duyckaerts, C.; Gasser, T.; Halliday, G. M., et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 8: 115 0 -11 57 ; 2 0 0 9 .
18. Halliday, G.; Lees, A.; Stern, M. Milestones in Parkinson's disease - clinical and pathologic features. Mov. Disord 26: 1015-1021; 2011.
19. Fearnley, J. M.; Lees, A. J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114(Pt 5): 2283-2301; 1991.
20. Dunning, C. J.; Reyes, J. F.; Steiner, J. A.; Brundin, P. Can Parkinson's disease pathology be propagated from one neuron to another? Prog. Neurobiol 97: 205-219; 2012.
21. Samii, A.; Nutt, J. G.; Ransom, B. R. Parkinson's disease. Lancet 363: 17 8 3 -1793; 2004. (Pubitemid 38698383)
22. George J.M. The synucleins. Genome Biol. 3:reviews3002; 2002.
23. Probst, A.; Bloch, A.; Tolnay, M. New insights into the pathology of Parkinson's disease: does the peripheral autonomic system become central? Eur. J. Neurol 15(Suppl. 1): 1-4; 2008. (Pubitemid 351421305)
24. Schapira, A. H.; Jenner, P. Etiology and pathogenesis of Parkinson's disease. Mov. Disord 26: 1049-1055; 2011.
25. Poskanzer, D. C.; Schwab, R. S. Cohort analysis of Parkinson's syndrome: evidence for a single etiology related to subclinical infection about 1920. J. Chronic Dis 16: 961-973; 1963.
26. Corti, O.; Lesage, S.; Brice, A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol. Rev 91: 116 1 -1218; 2011.
27. Lotharius, J.; O'Malley, K. L. Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity. Ann. Neurol 49: 79-89; 2001. (Pubitemid 32163008)
28. Klaidman, L. K.; Adams Jr. J. D.; Leung, A. C.; Kim, S. S.; Cadenas, E. Redox cycling of MPP+: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydro-genase. Free Radic. Biol. Med. 15: 169-179; 1993. (Pubitemid 23218819)
29. Langston, J. W.; Ballard, P.; Tetrud, J. W.; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980; 1983. (Pubitemid 13189531)
30. Ross, O. A.; Braithwaite, A. T.; Skipper, L. M.; Kachergus, J.; Hulihan, M. M.; Middleton, F. A., et al. Genomic investigation of a-synuclein multiplication and parkinsonism. Ann. Neurol. 63: 74 3 -750; 2008. (Pubitemid 351945533)
31. Betarbet, R.; Sherer, T. B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A. V.; Greenamyre, J. T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3: 1301-1306; 2000.
32. Sherer, T. B.; Kim, J. H.; Betarbet, R.; Greenamyre, J. T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and a-synu-clein aggregation. Exp. Neurol 179: 9-16; 20 03. (Pubitemid 36062614)
33. Sherer, T. B.; Betarbet, R.; Testa, C. M.; Seo, B. B.; Richardson, J. R.; Kim, J. H., et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23: 10756-10764; 2003. (Pubitemid 37499681)
34. Di Monte, D. A. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2: 531-538; 2003. (Pubitemid 36994992)
35. Elbaz, A.; Moisan, F. Update in the epidemiology of Parkinson's disease. Curr. Opin. Neurol. 21: 454-460; 2008.
36. Ascherio, A.; Zhang, S. M.; Hernan, M. A.; Kawachi, I.; Colditz, G. A.; Speizer, F. E., et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol 50: 56-63; 2001.
37. Warner, T. T.; Schapira, A. H. Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol 53(Suppl. 3):S16-S23; 2003.
38. Polymeropoulos, M. H.; Higgins, J. J.; Golbe, L. I.; Johnson, W. G.; Ide, S. E.; Di, I. G., et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274: 119 7 -1199; 1996. (Pubitemid 26389286)
39. Polymeropoulos, M. H.; Lavedan, C.; Leroy, E.; Ide, S. E.; Dehejia, A.; Dutra, A., et al. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047; 1997. (Pubitemid 27443610)
40. Spillantini, M. G.; Schmidt, M. L.; Lee, V. M.; Trojanowski, J. Q.; Jakes, R.; Goedert, M. a-Synuclein in Lewy bodies. Nature 388: 839-840; 1997.
41. Belin, A. C.; Westerlund, M. Parkinson's disease: a genetic perspective. FEBS J 275: 1377-1383; 2008. (Pubitemid 351388789)
42. Satake, W.; Nakabayashi, Y.; Mizuta, I.; Hirota, Y.; Ito, C.; Kubo, M., et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet 41: 13 03 -13 07 ; 20 0 9 .
43. Simon-Sanchez, J.; Schulte, C.; Bras, J. M.; Sharma, M.; Gibbs, J. R.; Berg, D., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet 41: 1308-1312; 2009.
44. Pankratz, N.; Wilk, J. B.; Latourelle, J. C.; DeStefano, A. L.; Halter, C.; Pugh, E. W., et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet. 124: 593-605; 2009.
45. Hamza, T. H.; Zabetian, C. P.; Tenesa, A.; Laederach, A.; Montimurro, J.; Yearout, D., et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet 42: 781-785; 2010.
46. Paisan-Ruiz, C.; Bhatia, K. P.; Li, A.; Hernandez, D.; Davis, M.; Wood, N. W., et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann. Neurol. 65: 19-23; 2009.
47. Di, F. A.; Dekker, M. C.; Montagna, P.; Baruzzi, A.; Yonova, E. H.; Correia, G. L., et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian- pyramidal syndrome. Neurology 72: 240-245; 2009.
48. Hicks, A. A.; Petursson, H.; Jonsson, T.; Stefansson, H.; Johannsdottir, H. S.; Sainz, J., et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. Neurol. 52: 549-555; 2002. (Pubitemid 35246857)
49. Lautier, C.; Goldwurm, S.; Durr, A.; Giovannone, B.; Tsiaras, W. G.; Pezzoli, G., et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am. J. Hum. Genet. 82: 822-833; 2008.
50. Leroy, E.; Boyer, R.; Auburger, G.; Leube, B.; Ulm, G.; Mezey, E., et al. The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452; 1998.
51. Gasser, T.; Muller-Myhsok, B.; Wszolek, Z. K.; Oehlmann, R.; Calne, D. B.; Bonifati, V., et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat. Genet 18: 262-265; 1998. (Pubitemid 28117265)
52. Strauss, K. M.; Martins, L. M.; Plun-Favreau, H.; Marx, F. P.; Kautzmann, S.; Berg, D., et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet 14: 2099-2111; 2005. (Pubitemid 41418010)
53. Pankratz, N.; Nichols, W. C.; Uniacke, S. K.; Halter, C.; Murrell, J.; Rudolph, A., et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum. Mol. Genet 12: 2599-2608; 2003. (Pubitemid 37304683)
54. Lesage, S.; Brice, A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet 18:R48-R59; 2009.
55. Paisan-Ruiz, C. LRRK2 gene variation and its contribution to Parkinson disease. Hum. Mutat 30: 115 3 -1160; 2009.
56. Kosaka, K.; Tsuchiya, K.; Yoshimura, M. Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin. Neuropathol 7: 299-305; 1988. (Pubitemid 19019180)
57. Braak, H.; Braak, E.; Yilmazer, D.; Schultz, C.; de Vos, R. A.; Jansen, E. N. Nigral and extranigral pathology in Parkinson's disease. J. Neural Transm. Suppl. 46: 15-31; 1995. (Pubitemid 26043220)
58. Macdonald, V.; Halliday, G. M. Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Mov. Disord 17: 1166-117 3 ; 2 0 0 2 . (Pubitemid 36041329)
59. Henderson, J. M.; Carpenter, K.; Cartwright, H.; Halliday, G. M. Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann. Neurol 47: 345-352; 2000. (Pubitemid 30141844)
60. McRitchie, D. A.; Cartwright, H. R.; Halliday, G. M. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp. Neurol 144: 202-213; 1997. (Pubitemid 27149624)
61. Bohnen, N. I.; Albin, R. L. The cholinergic system and Parkinson disease. Behav. Brain Res. 221: 564-573; 2011.
62. Fronczek, R.; Overeem, S.; Lee, S. Y.; Hegeman, I. M.; van, P. J.; van Duinen, S. G., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 130: 157 7 -15 85 ; 2007. (Pubitemid 47355929)
63. Thannickal, T. C.; Lai, Y. Y.; Siegel, J. M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130: 1586-1595; 2007. (Pubitemid 47355933)
64. Halliday, G. M.; Li, Y. W.; Blumbergs, P. C.; Joh, T. H.; Cotton, R. G.; Howe, P. R., et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann. Neurol. 27: 373-385; 1990. (Pubitemid 20132052)
65. Harding, A. J.; Stimson, E.; Henderson, J. M.; Halliday, G. M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 125: 2431-2445; 2002. (Pubitemid 35303503)
66. Kingsbury, A. E.; Bandopadhyay, R.; Silveira-Moriyama, L.; Ayling, H.; Kallis, C.; Sterlacci, W., et al. Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov. Disord 25: 2508-2515; 2010.
67. Hoogendijk, W. J.; Pool, C. W.; Troost, D.; van, Z. E.; Swaab, D. F. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain 118(Pt 1): 131-143; 1995.
68. Pedersen, K. M.; Marner, L.; Pakkenberg, H.; Pakkenberg, B. No global loss of neocortical neurons in Parkinson's disease: a quantitative stereological study. Mov. Disord 20: 164-171; 2005. (Pubitemid 40361119)
69. Double, K. L.; Halliday, G. M.; McRitchie, D. A.; Reid, W. G.; Hely, M. A.; Morris, J. G. Regional brain atrophy in idiopathic Parkinson's disease and diffuse Lewy body disease. Dementia 7: 304-313; 1996. (Pubitemid 26341259)
70. Dalaker, T. O.; Zivadinov, R.; Larsen, J. P.; Beyer, M. K.; Cox, J. L.; Alves, G., et al. Gray matter correlations of cognition in incident Parkinson's disease. Mov. Disord 25: 629-633; 2010.
71. Braak, H.; Del, T. K.; Bratzke, H.; Hamm-Clement, J.; Sandmann-Keil, D.; Rub, U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 249(Suppl. 3); 2002. III/1-III/5.
72. Braak, H.; Del, T. K.; Rub, U.; de Vos, R. A.; Jansen Steur, E. N.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24: 197-211; 2003. (Pubitemid 36007810)
73. Braak, H.; Ghebremedhin, E.; Rub, U.; Bratzke, H.; Del, T. K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121-134; 2004. (Pubitemid 39362633)
74. Duda, J. E.; Lee, V. M.; Trojanowski, J. Q. Neuropathology of synuclein aggregates. J. Neurosci. Res. 61: 121-127; 2000.
75. Halliday, G. M.; McCann, H. The progression of pathology in Parkinson's disease. Ann. N. Y. Acad. Sci. 1184: 188-195; 2010.
76. Hawkes, C. H.; Del, T. K.; Braak, H. A timeline for Parkinson's disease. Parkinsonism Relat. Disord. 16: 79-84; 2010.
77. Brundin, P.; Li, J. Y.; Holton, J. L.; Lindvall, O.; Revesz, T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat. Rev. Neurosci. 9: 741-745; 2008.
78. Kalaitzakis, M. E.; Graeber, M. B.; Gentleman, S. M.; Pearce, R. K. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of a-synuclein staging. Neuropathol. Appl. Neuro-biol 34: 284-295; 2008. (Pubitemid 351590870)
79. Attems, J.; Jellinger, K. A. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease. Neuropathol. Appl. Neurobiol 34: 466-467; 2008.
80. Tsang, A. H.; Chung, K. K. Oxidative and nitrosative stress in Parkinson's disease. Biochim. Biophys. Acta 1792: 643-650; 2009.
81. Danielson, S. R.; Andersen, J. K. Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic. Biol. Med. 44: 1787-1794; 2008.
82. Seet, R. C.; Lee, C. Y.; Lim, E. C.; Tan, J. J.; Quek, A. M.; Chong, W. L., et al. Oxidative damage in Parkinson disease: measurement using accurate bio-markers. Free Radic. Biol. Med. 48: 560-566; 2010.
83. Navarro, A.; Boveris, A. Brain mitochondrial dysfunction and oxidative damage in Parkinson's disease. J. Bioenerg. Biomembr 41: 517-521; 2009.
84. Betarbet, R.; Sherer, T. B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A. V.; Greenamyre, J. T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3: 1301-1306; 2000.
85. Dexter, D. T.; Carter, C. J.; Wells, F. R.; Javoy-Agid, F.; Agid, Y.; Lees, A., et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem 52: 381-389; 1989. (Pubitemid 19037600)
86. Yoritaka, A.; Hattori, N.; Uchida, K.; Tanaka, M.; Stadtman, E. R.; Mizuno, Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA 93: 2696-2701; 1996. (Pubitemid 26114311)
87. Alam, Z. I.; Jenner, A.; Daniel, S. E.; Lees, A. J.; Cairns, N.; Marsden, C. D., et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem 69: 11 9 6 -1203; 1997. (Pubitemid 27364841)
88. Zhang, J.; Perry, G.; Smith, M. A.; Robertson, D.; Olson, S. J.; Graham, D. G., et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol 154: 1423-1429; 1999. (Pubitemid 29226437)
89. Alam, Z. I.; Daniel, S. E.; Lees, A. J.; Marsden, D. C.; Jenner, P.; Halliwell, B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem 69: 1326-1329; 1997. (Pubitemid 27364859)
90. Floor, E.; Wetzel, M. G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem 70: 268-275; 1998. (Pubitemid 28020852)
91. Good, P. F.; Hsu, A.; Werner, P.; Perl, D. P.; Olanow, C. W. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57: 338-342; 1998. (Pubitemid 28182632)
92. Duda, J. E.; Giasson, B. I.; Chen, Q.; Gur, T. L.; Hurtig, H. I.; Stern, M. B., et al. Widespread nitration of pathological inclusions in neurodegenerative synu-cleinopathies. Am. J. Pathol. 157: 1439-1445; 2000.
93. Ferrante, R. J.; Hantraye, P.; Brouillet, E.; Beal, M. F. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res 823: 17 7 -182; 1999. (Pubitemid 29225506)
94. Pennathur, S.; Jackson-Lewis, V.; Przedborski, S.; Heinecke, J. W. Mass spectrometric quantification of 3-"nitrotyrosine, ortho-tyrosine, and o,o0 -dityrosine in brain tissue of 1-"methyl-4-phenyl-1,2,3,6-tetrahydropyr- idine-treated mice, a model of oxidative stress in Parkinson's disease. J. Biol. Chem 274: 34621-34628; 1999. (Pubitemid 129509499)
95. Perry, T. L.; Godin, D. V.; Hansen, S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33: 305-310; 1982. (Pubitemid 13119539)
96. Perry, T. L.; Yong, V. W. Idiopathic Parkinson's disease, progressive supra-nuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett 67: 269-274; 1986. (Pubitemid 16038336)
97. Pearce, R. K.; Owen, A.; Daniel, S.; Jenner, P.; Marsden, C. D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm 104: 661-677; 1997. (Pubitemid 27474680)
98. Hirsch, E. C. Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann. Neurol 32(Suppl):S88-S93; 1992.
99. Sulzer, D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 30: 244-250; 2007. (Pubitemid 46667168)
100. Zecca, L.; Tampellini, D.; Gerlach, M.; Riederer, P.; Fariello, R. G.; Sulzer, D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol. Pathol 54: 414-418; 2001. (Pubitemid 34025257)
101. Dexter, D. T.; Wells, F. R.; Lees, A. J.; Agid, F.; Agid, Y.; Jenner, P., et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem 52: 1830-1836; 1989. (Pubitemid 19140770)
102. Gutteridge, J. M. Hydroxyl radicals, iron, oxidative stress, and neurodegen-eration. Ann. N. Y. Acad. Sci. 738: 201-213; 1994.
103. Zecca, L.; Casella, L.; Albertini, A.; Bellei, C.; Zucca, F. A.; Engelen, M., et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J. Neurochem 106: 1866-1875; 2008.
104. Sian-Hulsmann, J.; Mandel, S.; Youdim, M. B.; Riederer, P. The relevance of iron in the pathogenesis of Parkinson's disease. J. Neurochem 11 8 : 939-957; 2011.
105. Bougria, M.; Vitorica, J.; Cano, J.; Machado, A. Implication of dopamine transporter system on 1-methyl-4-phenylpyridinium and rotenone effect in striatal synaptosomes. Eur. J. Pharmacol 291: 407-415; 1995. (Pubitemid 3014609)
106. Gomez, C.; Bandez, M. J.; Navarro, A. Pesticides and impairment of mito-chondrial function in relation with the parkinsonian syndrome. Front. Biosci 12: 1079-1093; 2007. (Pubitemid 46846880)
107. Henchcliffe, C.; Beal, M. F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 4: 600-609; 2008.
108. Kudin, A. P.; Bimpong-Buta, N. Y.; Vielhaber, S.; Elger, C. E.; Kunz, W. S. Characterization of superoxide-producing sites in isolated brain mitochondria. J. Biol. Chem. 279: 4127-4135; 2004. (Pubitemid 38198997)
109. Janetzky, B.; Hauck, S.; Youdim, M. B.; Riederer, P.; Jellinger, K.; Pantucek, F., et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci. Lett 169: 126-128; 1994. (Pubitemid 24108879)
110. Schapira, A. H.; Cooper, J. M.; Dexter, D.; Clark, J. B.; Jenner, P.; Marsden, C. D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54: 823-827; 1990.
111. Schapira, A. H.; Cooper, J. M.; Dexter, D.; Jenner, P.; Clark, J. B.; Marsden, C. D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1: 1269; 1989. (Pubitemid 19140359)
112. Mann, V. M.; Cooper, J. M.; Krige, D.; Daniel, S. E.; Schapira, A. H.; Brain, Marsden C. D. skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115(Pt 2): 333-342; 1992.
113. Navarro, A.; Boveris, A.; Bandez, M. J.; Sanchez-Pino, M. J.; Gomez, C.; Muntane, G., et al. Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radic. Biol. Med 46: 1574-1580; 2009.
114. Keeney, P. M.; Xie, J.; Capaldi, R. A.; Bennett Jr. J. P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci 26: 5256-5264; 2006. (Pubitemid 44315308)
115. Szabo, C.; Ischiropoulos, H.; Radi, R. Peroxynitrite: biochemistry, pathophy-siology and development of therapeutics. Nat. Rev. Drug Discovery 6: 662-680; 2007. (Pubitemid 47207751)
116. Brown, G. C.; Borutaite, V. Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim. Biophys. Acta 44-49: 2004; 1658.
117. Hastings, T. G. The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease. J. Bioenerg. Biomembr 41: 469-472; 2009.
118. Staal, R. G.; Mosharov, E. V.; Sulzer, D. Dopamine neurons release transmitter via a flickering fusion pore. Nat. Neurosci. 7: 341-346; 2004. (Pubitemid 38429173)
119. Caudle, W. M.; Colebrooke, R. E.; Emson, P. C.; Miller, G. W. Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci. 31: 303-308; 2008.
120. Mosharov, E. V.; Staal, R. G.; Bove, J.; Prou, D.; Hananiya, A.; Markov, D., et al. a-Synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci. 26: 9304-9311; 2006. (Pubitemid 44359856)
121. Shih, J. C.; Chen, K.; Ridd, M. J. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 22: 197-217; 1999. (Pubitemid 29144886)
122. Stokes, A. H.; Hastings, T. G.; Vrana, K. E. Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 55: 659-665; 1999. (Pubitemid 29173480)
123. Mazzulli, J. R.; Mishizen, A. J.; Giasson, B. I.; Lynch, D. R.; Thomas, S. A.; Nakashima, A., et al. Cytosolic catechols inhibit a-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci 26: 10068-10078; 2006. (Pubitemid 44477168)
124. LaVoie, M. J.; Ostaszewski, B. L.; Weihofen, A.; Schlossmacher, M. G.; Selkoe, D. J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med 11 : 1214-1221; 2005. (Pubitemid 43093669)
125. Van Laar, V. S.; Mishizen, A. J.; Cascio, M.; Hastings, T. G. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol. Dis 34: 487-500; 2009.
126. Kuhn, D. M.; Arthur Jr. R. E.; Thomas, D. M.; Elferink, L. A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem 73: 1309-1317; 1999. (Pubitemid 29395493)
127. Conway, K. A.; Rochet, J. C.; Bieganski, R. M.; Lansbury Jr. P. T. Kinetic stabilization of the a-synuclein protofibril by a dopamine-a-synuclein adduct. Science 294: 1346-1349; 2001. (Pubitemid 33063102)
128. Mauceli, G.; Busceti, C. I.; Pellegrini, A.; Soldani, P.; Lenzi, P.; Paparelli, A., et al. Overexpression of a-synuclein following methamphetamine: is it good or bad? Ann. N. Y. Acad. Sci. 1074: 191-197; 2006. (Pubitemid 44532824)
129. Xu, J.; Kao, S. Y.; Lee, F. J.; Song, W.; Jin, L. W.; Yankner, B. A. Dopamine-dependent neurotoxicity of a-synuclein: a mechanism for selective neuro-degeneration in Parkinson disease. Nat. Med 8: 600-606; 2002. (Pubitemid 34633438)
130. Lee, F. J.; Liu, F.; Pristupa, Z. B.; Niznik, H. B. Direct binding and functional coupling of a-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 15: 916-926; 2001. (Pubitemid 32290778)
131. Michel, P. P.; Ruberg, M.; Hirsch, E. Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease? Sci. STKE 2006 :e19; 2006.
132. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53(Suppl. 3): S26-S36; 2003.
133. Greenamyre, J. T.; Hastings, T. G. Parkinson's - divergent causes, convergent mechanisms. Science 304: 1120 -1122; 2004. (Pubitemid 38661838)
134. Volbracht, C.; van, B. J.; Zhu, C.; Blomgren, K.; Leist, M. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur. J. Neurosci 23: 2611-2622; 2006. (Pubitemid 43801453)
135. Turski, L.; Bressler, K.; Rettig, K. J.; Loschmann, P. A.; Wachtel, H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349: 414-418; 1991. (Pubitemid 21926101)
136. Zuddas, A.; Oberto, G.; Vaglini, F.; Fascetti, F.; Fornai, F.; Corsini, G. U. MK-801 prevents 1-"methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J. Neurochem. 59: 733-739; 1992.
137. Tabatabaei, A.; Perry, T. L.; Hansen, S.; Krieger, C. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice. Neurosci. Lett 141: 192-194; 1992.
138. Brouillet, E.; Beal, M. F. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. Neuroreport 4: 387-390; 1993. (Pubitemid 23116729)
139. Johnson, K. A.; Conn, P. J.; Niswender, C. M. Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol. Disord. Drug Targets 8: 475-491; 2009.
140. Greenamyre, J. T. Glutamatergic influences on the basal ganglia. Clin. Neuropharmacol. 24: 65-70; 2001. (Pubitemid 32294680)
141. McCormack, J. G.; Halestrap, A. P.; Denton, R. M. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol. Rev. 70: 391-425; 1990. (Pubitemid 20140186)
142. Kowaltowski, A. J.; de Souza-Pinto, N. C.; Castilho, R. F.; Vercesi, A. E. Mitochondria and reactive oxygen species. Free Radic. Biol. Med. 47: 333-343; 2009.
143. Sheehan, J. P.; Swerdlow, R. H.; Parker, W. D.; Miller, S. W.; Davis, R. E.; Tuttle, J. B. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J. Neurochem. 68: 1221-1233 ; 1997. (Pubitemid 27086228)
144. Esteves, A. R.; Arduino, D. M.; Swerdlow, R. H.; Oliveira, C. R.; Cardoso, S. M. Oxidative stress involvement in a-synuclein oligomerization in Parkinson's disease cybrids. Antioxid. Redox Signaling 11 : 439-448; 2009.
145. Lucking, C. B.; Durr, A.; Bonifati, V.; Vaughan, J.; De, M. G.; Gasser, T., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342: 1560-1567; 2000. (Pubitemid 30340501)
146. Bonifati, V.; Rizzu, P.; van Baren, M. J.; Schaap, O.; Breedveld, G. J.; Krieger, E., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259; 2003. (Pubitemid 36131051)
147. Valente, E. M.; Abou-Sleiman, P. M.; Caputo, V.; Muqit, M. M.; Harvey, K.; Gispert, S., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304: 115 8 -1160; 2004. (Pubitemid 38661852)
148. Henchcliffe, C.; Beal, M. F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 4: 600-609; 2008.
149. Kruger, R.; Kuhn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S., et al. Ala30Pro mutation in the gene encoding a-synuclein in Parkinson's disease. Nat. Genet 18 : 106-108; 1998.
150. Zarranz, J. J.; Alegre, J.; Gomez-Esteban, J. C.; Lezcano, E.; Ros, R.; Ampuero, I., et al. The new mutation, E46K, of a-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55: 164-173; 2004. (Pubitemid 38166992)
151. Ueda, K.; Fukushima, H.; Masliah, E.; Xia, Y.; Iwai, A.; Yoshimoto, M., et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90: 11 2 8 2 -11286; 1993. (Pubitemid 23354413)
152. Giasson, B. I.; Murray, I. V.; Trojanowski, J. Q.; Lee, V. M. A hydrophobic stretch of 12 amino acid residues in the middle of a-synuclein is essential for filament assembly. J. Biol. Chem 276: 2380-2386; 2001.
153. Fortin, D. L.; Troyer, M. D.; Nakamura, K.; Kubo, S.; Anthony, M. D.; Edwards, R. H. Lipid rafts mediate the synaptic localization of a-synuclein. J. Neurosci. 24: 6715-6723; 2004. (Pubitemid 38993891)
154. Eliezer, D.; Kutluay, E.; Bussell Jr. R.; Browne, G. Conformational properties of a-synuclein in its free and lipid-associated states. J. Mol. Biol 307: 10 61 -1073; 2001. (Pubitemid 33029953)
155. George, J. M.; Jin, H.; Woods, W. S.; Clayton, D. F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15: 361-372; 1995.
156. Abeliovich, A.; Schmitz, Y.; Farinas, I.; Choi-Lundberg, D.; Ho, W. H.; Castillo, P. E., et al. Mice lacking a-synuclein display functional deficits in
157. Sidhu, A.; Wersinger, C.; Vernier, P. Does a-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J 18: 637-647; 2004. (Pubitemid 38451786)
158. Sulzer, D. Clues to how a-synuclein damages neurons in Parkinson's disease. Mov. Disord 25(Suppl. 1):S27-S31; 2010.
159. Norris, E. H.; Giasson, B. I.; Hodara, R.; Xu, S.; Trojanowski, J. Q.; Ischiropoulos, H., et al. Reversible inhibition of a-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280: 21212-21219; 2005. (Pubitemid 40805683)
160. Volles, M. J.; Lee, S. J.; Rochet, J. C.; Shtilerman, M. D.; Ding, T. T.; Kessler, J. C., et al. Vesicle permeabilization by protofibrillar a-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40: 7812-7819; 2001. (Pubitemid 32622972)
161. Sulzer, D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 30: 244-250; 2007. (Pubitemid 46667168)
162. Bennett, M. C.; Bishop, J. F.; Leng, Y.; Chock, P. B.; Chase, T. N.; Mouradian, M. M. Degradation of a-synuclein by proteasome. J. Biol. Chem. 274: 33855-33858; 1999.
163. Tofaris, G. K.; Layfield, R.; Spillantini, M. G. a-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the protea-some. FEBS Lett 509: 22-26; 2001. (Pubitemid 33153074)
164. Rideout, H. J.; Larsen, K. E.; Sulzer, D.; Stefanis, L. Proteasomal inhibition leads to formation of ubiquitin/a-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem 78: 899-908; 2001. (Pubitemid 32777990)
165. Rideout, H. J.; Stefanis, L. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol. Cell. Neurosci 21: 223-238; 2002. (Pubitemid 35333814)
166. Paxinou, E.; Chen, Q.; Weisse, M.; Giasson, B. I.; Norris, E. H.; Rueter, S. M., et al. Induction of a-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21: 8053-8061; 2001. (Pubitemid 32952762)
167. Webb, J. L.; Ravikumar, B.; Atkins, J.; Skepper, J. N.; Rubinsztein, D. C. a-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278: 25009-25013; 2003. (Pubitemid 37548663)
168. Lee, H. J.; Khoshaghideh, F.; Patel, S.; Lee, S. J. Clearance of a-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci 24: 1888-1896; 2004. (Pubitemid 38292800)
169. Cheung, Z. H.; Ip, N. Y. The emerging role of autophagy in Parkinson's disease. Mol. Brain 2: 29; 2009.
170. Cuervo, A. M.; Stefanis, L.; Fredenburg, R.; Lansbury, P. T.; Sulzer, D. Impaired degradation of mutant a-synuclein by chaperone-mediated autophagy. Science 305: 1292-1295; 2004. (Pubitemid 39129234)
171. Petrucelli, L.; O'Farrell, C.; Lockhart, P. J.; Baptista, M.; Kehoe, K.; Vink, L., et al. Parkin protects against the toxicity associated with mutant a-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36: 1007-1019; 20 02. (Pubitemid 36044504)
172. Snyder, H.; Mensah, K.; Theisler, C.; Lee, J.; Matouschek, A.; Wolozin, B. Aggregated and monomeric a-synuclein bind to the S60 proteasomal protein and inhibit proteasomal function. J. Biol. Chem 278: 11753-11759; 2003. (Pubitemid 36800143)
173. Tanaka, Y.; Engelender, S.; Igarashi, S.; Rao, R. K.; Wanner, T.; Tanzi, R. E., et al. Inducible expression of mutant a-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet 10: 919-926; 2001. (Pubitemid 32401408)
174. Vogiatzi, T.; Xilouri, M.; Vekrellis, K.; Stefanis, L. Wild type a-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem 283: 23542-23556; 2008.
175. Zhang, Y.; Dawson, V. L.; Dawson, T. M. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol. Dis 7: 240-250; 2000.
176. Hashimoto, M.; Takeda, A.; Hsu, L. J.; Takenouchi, T.; Masliah, E. Role of cytochrome c as a stimulator of a-synuclein aggregation in Lewy body disease. J. Biol. Chem 274: 28849-28852; 1999.
177. Norris, E. H.; Uryu, K.; Leight, S.; Giasson, B. I.; Trojanowski, J. Q.; Lee, V. M. Pesticide exposure exacerbates a-synucleinopathy in an A53T transgenic mouse model. Am. J. Pathol. 170: 658-666; 2007. (Pubitemid 47339402)
178. Manning-Bog, A. B.; McCormack, A. L.; Li, J.; Uversky, V. N.; Fink, A. L.; Di Monte, D. A. The herbicide paraquat causes up-regulation and aggregation of a-synu-clein in mice: paraquat and a-synuclein. J. Biol. Chem 277: 16 41 -1644; 2002. (Pubitemid 34968732)
179. Dauer, W.; Kholodilov, N.; Vila, M.; Trillat, A. C.; Goodchild, R.; Larsen, K. E., et al. Resistance of a-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 99: 14524-14529; 2002. (Pubitemid 35257704)
180. Kalivendi, S. V.; Yedlapudi, D.; Hillard, C. J.; Kalyanaraman, B. Oxidants induce alternative splicing of a-synuclein: implications for Parkinson's disease. Free Radic. Biol. Med. 48: 377-383; 2010.
181. Devi, L.; Raghavendran, V.; Prabhu, B. M.; Avadhani, N. G.; Anandatheertha-varada, H. K. Mitochondrial import and accumulation of a-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem 283: 9089-9100; 2008.
182. Cole, N. B.; Dieuliis, D.; Leo, P.; Mitchell, D. C.; Nussbaum, R. L. Mitochondrial translocation of a-synuclein is promoted by intracellular acidification. Exp. Cell Res. 314: 2076-2089; 2008.
183. Shavali, S.; Brown-Borg, H. M.; Ebadi, M.; Porter, J. Mitochondrial localization of a-synuclein protein in a-synuclein overexpressing cells. Neurosci. Lett 439: 125-128; 2008.
184. Parihar, M. S.; Parihar, A.; Fujita, M.; Hashimoto, M.; Ghafourifar, P. a-Synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuro-blastoma cells. Int. J. Biochem. Cell Biol 41: 2015-2024; 2009.
185. Martin, L. J.; Pan, Y.; Price, A. C.; Sterling, W.; Copeland, N. G.; Jenkins, N. A., et al. Parkinson's disease a-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci 26: 41-50; 2006. (Pubitemid 43089519)
186. Parihar, M. S.; Parihar, A.; Fujita, M.; Hashimoto, M.; Ghafourifar, P. Mito-chondrial association of a-synuclein causes oxidative stress. Cell. Mol. Life Sci. 65: 1272-1284; 2008.
187. Buttner, S.; Bitto, A.; Ring, J.; Augsten, M.; Zabrocki, P.; Eisenberg, T., et al. Functional mitochondria are required for a-synuclein toxicity in aging yeast. J. Biol. Chem 283: 7554-7560; 2008.
188. Anderson, J. P.; Walker, D. E.; Goldstein, J. M.; de, L. R.; Banducci, K.; Caccavello, R. J., et al. Phosphorylation of Ser-129 is the dominant pathological modification of a-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem 281: 29739-29752; 2006. (Pubitemid 44536983)
189. Baba, M.; Nakajo, S.; Tu, P. H.; Tomita, T.; Nakaya, K.; Lee, V. M., et al. Aggregation of a-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol 152: 879-884; 1998. (Pubitemid 28173348)
190. Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M. S., et al. a-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4: 160-164; 2002.
191. Giasson, B. I.; Duda, J. E.; Murray, I. V.; Chen, Q.; Souza, J. M.; Hurtig, H. I., et al. Oxidative damage linked to neurodegeneration by selective a-synuclein nitration in synucleinopathy lesions. Science 290: 985-989; 2000.
192. Hasegawa, M.; Fujiwara, H.; Nonaka, T.; Wakabayashi, K.; Takahashi, H.; Lee, V. M., et al. Phosphorylated a-synuclein is ubiquitinated in a-synucleinopathy lesions. J. Biol. Chem. 277: 49071-49076; 2002. (Pubitemid 35470880)
193. Tofaris, G. K.; Razzaq, A.; Ghetti, B.; Lilley, K. S.; Spillantini, M. G. Ubiquitination of a-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem 278: 44405-44411; 2003. (Pubitemid 37377190)
194. Healy, D. G.; Falchi, M.; O'Sullivan, S. S.; Bonifati, V.; Durr, A.; Bressman, S., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7: 583-590; 2008.
195. Mata, I. F.; Wedemeyer, W. J.; Farrer, M. J.; Taylor, J. P.; Gallo, K. A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29: 286-293; 2006.
196. Bosgraaf, L.; Roc, Van Haastert P. J. a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta 1643: 5-10; 20 03.
197. Greggio, E.; Zambrano, I.; Kaganovich, A.; Beilina, A.; Taymans, J. M.; Daniels, V., et al. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem 283: 16906-16914; 2008.
198. Imai, Y.; Gehrke, S.; Wang, H. Q.; Takahashi, R.; Hasegawa, K.; Oota, E., et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27: 2432-2443; 2008.
199. Jaleel, M.; Nichols, R. J.; Deak, M.; Campbell, D. G.; Gillardon, F.; Knebel, A., et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J 405: 307-317; 2007. (Pubitemid 47075166)
200. West, A. B.; Moore, D. J.; Biskup, S.; Bugayenko, A.; Smith, W. W.; Ross, C. A., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA 102 : 16 8 4 2-16847; 2005. (Pubitemid 41688864)
201. Guo, L.; Gandhi, P. N.; Wang, W.; Petersen, R. B.; Wilson-Delfosse, A. L.; Chen, S. G. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell Res 313: 3658-3670; 2007. (Pubitemid 47404550)
202. Ito, G.; Okai, T.; Fujino, G.; Takeda, K.; Ichijo, H.; Katada, T., et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46: 1380-1388; 2007. (Pubitemid 46208485)
203. Burbulla, L. F.; Kruger, R. Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease. J. Neurol. Sci 306: 1-8; 2011.
204. Smith, W. W.; Pei, Z.; Jiang, H.; Dawson, V. L.; Dawson, T. M.; Ross, C. A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9: 1231-1233; 2006. (Pubitemid 44454261)
205. Di, F. A.; Rohe, C. F.; Ferreira, J.; Chien, H. F.; Vacca, L.; Stocchi, F., et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365: 412-415; 2005. (Pubitemid 40179228)
206. Gilks, W. P.; Abou-Sleiman, P. M.; Gandhi, S.; Jain, S.; Singleton, A.; Lees, A. J., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365: 415-416; 2005. (Pubitemid 40179229)
207. Nichols, W. C.; Pankratz, N.; Hernandez, D.; Paisan-Ruiz, C.; Jain, S.; Halter, C. A., et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365: 410-412; 2005. (Pubitemid 40179227)
208. Giasson, B. I.; Covy, J. P.; Bonini, N. M.; Hurtig, H. I.; Farrer, M. J.; Trojanowski, J. Q., et al. Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59: 315-322; 2006. (Pubitemid 43202485)
209. Ross, O. A.; Toft, M.; Whittle, A. J.; Johnson, J. L.; Papapetropoulos, S.; Mash, D. C., et al. Lrrk2 and Lewy body disease. Ann. Neurol. 59: 388-393; 2006. (Pubitemid 43202496)
210. Tong, Y.; Yamaguchi, H.; Giaime, E.; Boyle, S.; Kopan, R.; Kelleher III R. J., et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of a-synuclein, and apoptotic cell death in aged mice. Proc. Natl. Acad. Sci. USA 107: 9879-9884; 2010.
211. Mortiboys, H.; Johansen, K. K.; Aasly, J. O.; Bandmann, O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75: 2017-2020; 2010.
212. Nguyen, H. N.; Byers, B.; Cord, B.; Shcheglovitov, A.; Byrne, J.; Gujar, P., et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8: 267-280; 2011.
213. Criscuolo, C.; Volpe, G.; De, R. A.; Varrone, A.; Marongiu, R.; Mancini, P., et al. PINK1 homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism. Mov. Disord 21: 1265-1267; 2006. (Pubitemid 44336626)
214. Lucking, C. B.; Bonifati, V.; Periquet, M.; Vanacore, N.; Brice, A.; Meco, G. Pseudo-dominant inheritance and exon 2 triplication in a family with parkin gene mutations. Neurology 57: 924-927; 2001. (Pubitemid 32845526)
215. Maruyama, M.; Ikeuchi, T.; Saito, M.; Ishikawa, A.; Yuasa, T.; Tanaka, H., et al. Novel mutations, pseudo-dominant inheritance, and possible familial affects in patients with autosomal recessive juvenile parkinsonism. Ann. Neurol 48: 245-250; 2000. (Pubitemid 30617044)
216. Lucking, C. B.; Chesneau, V.; Lohmann, E.; Verpillat, P.; Dulac, C.; Bonnet, A. M., et al. Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease. Arch. Neurol 60: 1253-1256; 2003. (Pubitemid 37099631)
217. Periquet, M.; Latouche, M.; Lohmann, E.; Rawal, N.; De, M. G.; Ricard, S., et al. Parkin mutations are frequent in patients with isolated early-onset parkin-sonism. Brain 126: 1271-1278; 2003. (Pubitemid 36644374)
218. Takahashi, H.; Ohama, E.; Suzuki, S.; Horikawa, Y.; Ishikawa, A.; Morita, T., et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 44: 437-441; 1994. (Pubitemid 24098141)
219. Farrer, M.; Chan, P.; Chen, R.; Tan, L.; Lincoln, S.; Hernandez, D., et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol 50: 293-300; 2001. (Pubitemid 32848731)
220. Moore, D. J. Parkin: a multifaceted ubiquitin ligase. Biochem. Soc. Trans. 34: 74 9 -753; 2006. (Pubitemid 44796412)
221. Shimura, H.; Schlossmacher, M. G.; Hattori, N.; Frosch, M. P.; Trockenbacher, A.; Schneider, R., et al. Ubiquitination of a new form of a-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293: 263-269; 2001. (Pubitemid 32694735)
222. Corti, O.; Hampe, C.; Koutnikova, H.; Darios, F.; Jacquier, S.; Prigent, A., et al. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum. Mol. Genet 12: 1427-1437; 2003. (Pubitemid 36758455)
223. von, C. R.; Dawson, V. L.; Dawson, T. M. Parkin-associated Parkinson's disease. Cell Tissue Res. 318: 17 5 -184; 2004. (Pubitemid 39362637)
224. Shimura, H.; Hattori, N.; Kubo, S.; Mizuno, Y.; Asakawa, S.; Minoshima, S., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25: 302-305; 2000. (Pubitemid 30437317)
225. Kubo, S. I.; Kitami, T.; Noda, S.; Shimura, H.; Uchiyama, Y.; Asakawa, S., et al. Parkin is associated with cellular vesicles. J. Neurochem. 78: 42-54; 2001. (Pubitemid 32622587)
226. Mouatt-Prigent, A.; Muriel, M. P.; Gu, W. J.; El Hachimi, K. H.; Lucking, C. B.; Brice, A., et al. Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia. J. Neural Transm. 111 : 1209-1218; 2004. (Pubitemid 39468386)
227. Darios, F.; Corti, O.; Lucking, C. B.; Hampe, C.; Muriel, M. P.; Abbas, N., et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet 12: 517-526; 2003. (Pubitemid 36305590)
228. Cookson, M. R.; Lockhart, P. J.; McLendon, C.; O'Farrell, C.; Schlossmacher, M.; Farrer, M. J. RING finger 1 mutations in Parkin produce altered localization of the protein. Hum. Mol. Genet 12: 2957-2965; 2003. (Pubitemid 37442024)
229. Gu, W. J.; Corti, O.; Araujo, F.; Hampe, C.; Jacquier, S.; Lucking, C. B., et al. The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates. Neurobiol. Dis 14: 357-364; 2003. (Pubitemid 37543515)
230. Wang, C.; Tan, J. M.; Ho, M. W.; Zaiden, N.; Wong, S. H.; Chew, C. L., et al. Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. J. Neurochem 93: 422-431; 2005. (Pubitemid 40547499)
231. Kuroda, Y.; Mitsui, T.; Kunishige, M.; Shono, M.; Akaike, M.; Azuma, H., et al. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum. Mol. Genet 15: 883-895; 2006. (Pubitemid 43338230)
232. Palacino, J. J.; Sagi, D.; Goldberg, M. S.; Krauss, S.; Motz, C.; Wacker, M., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279: 18 614 -18622; 2004. (Pubitemid 38623283)
233. Stichel, C. C.; Zhu, X. R.; Bader, V.; Linnartz, B.; Schmidt, S.; Lubbert, H. Mono-and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum. Mol. Genet 16: 2377-2393; 2007. (Pubitemid 47514484)
234. Greene, J. C.; Whitworth, A. J.; Kuo, I.; Andrews, L. A.; Feany, M. B.; Pallanck, L. J. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. USA 10 0: 4078-4083; 2003. (Pubitemid 36418160)
235. Pesah, Y.; Pham, T.; Burgess, H.; Middlebrooks, B.; Verstreken, P.; Zhou, Y., et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131 : 2183-2194; 2004. (Pubitemid 38702049)
236. Machida, Y.; Chiba, T.; Takayanagi, A.; Tanaka, Y.; Asanuma, M.; Ogawa, N., et al. Common anti-apoptotic roles of parkin and a-synuclein in human dopaminergic cells. Biochem. Biophys. Res. Commun 332: 233-240; 2005. (Pubitemid 40719478)
237. Rothfuss, O.; Fischer, H.; Hasegawa, T.; Maisel, M.; Leitner, P.; Miesel, F., et al. Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum. Mol. Genet 18: 3832-3850; 2009.
238. Valente, E. M.; Bentivoglio, A. R.; Dixon, P. H.; Ferraris, A.; Ialongo, T.; Frontali, M., et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 68: 895-900; 2001. (Pubitemid 32289735)
239. Bonifati, V.; Rohe, C. F.; Breedveld, G. J.; Fabrizio, E.; De, M. M.; Tassorelli, C., et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65: 87-95; 2005. (Pubitemid 40967781)
240. Tan, E. K.; Yew, K.; Chua, E.; Puvan, K.; Shen, H.; Lee, E., et al. PINK1 mutations in sporadic early-onset Parkinson's disease. Mov. Disord 21: 789-793; 2006. (Pubitemid 44028298)
241. Hatano, Y.; Sato, K.; Elibol, B.; Yoshino, H.; Yamamura, Y.; Bonifati, V., et al. PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations. Neurology 63: 1482-1485; 2004. (Pubitemid 39426286)
242. Gandhi, S.; Muqit, M. M.; Stanyer, L.; Healy, D. G.; Abou-Sleiman, P. M.; Hargreaves, I., et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 129: 17 2 0 -17231; 2006.
243. Exner, N.; Treske, B.; Paquet, D.; Holmstrom, K.; Schiesling, C.; Gispert, S., et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci 27: 12413-12418; 2007. (Pubitemid 350085485)
244. Atsumi, M.; Li, Y.; Tomiyama, H.; Sato, K.; Hattori, N. [A 62-year-old woman with early-onset Parkinson's disease associated with the PINKi gene deletion]. Rinsho Shinkeigaku 46: 199-202; 2006. (Pubitemid 43761969)
245. Valente, E. M.; Salvi, S.; Ialongo, T.; Marongiu, R.; Elia, A. E.; Caputo, V., et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 56: 336-341; 2004. (Pubitemid 39166552)
246. Hoepken, H. H.; Gispert, S.; Morales, B.; Wingerter, O.; Del, T. D.; Mulsch, A., et al. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol. Dis. 25: 401-411; 2007. (Pubitemid 46124020)
247. Clark, I. E.; Dodson, M. W.; Jiang, C.; Cao, J. H.; Huh, J. R.; Seol, J. H., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441: 116 2 -1166; 2006. (Pubitemid 43990738)
248. Petit, A.; Kawarai, T.; Paitel, E.; Sanjo, N.; Maj, M.; Scheid, M., et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J. Biol. Chem 280: 34025-34032; 2005. (Pubitemid 41443124)
249. Wood-Kaczmar, A.; Gandhi, S.; Yao, Z.; Abramov, A. Y.; Miljan, E. A.; Keen, G., et al. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One 3:e2455; 2008.
250. Park, J.; Lee, S. B.; Lee, S.; Kim, Y.; Song, S.; Kim, S., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441: 115 7 -1161; 2 0 0 6 . (Pubitemid 43990737)
251. Yang, Y.; Gehrke, S.; Imai, Y.; Huang, Z.; Ouyang, Y.; Wang, J. W., et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. USA 103: 10793-10798; 2006. (Pubitemid 44078055)
252. Goldman, S. J.; Taylor, R.; Zhang, Y.; Jin, S. Autophagy and the degradation of mitochondria. Mitochondrion 10: 309-315; 2010.
253. Kim, I.; Rodriguez-Enriquez, S.; Lemasters, J. J. Selective degradation of mitochondria by mitophagy. Arch. Biochem. Biophys. 462: 245-253; 2007. (Pubitemid 46876640)
254. Narendra, D.; Tanaka, A.; Suen, D. F.; Youle, R. J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol 183: 795-803; 2008.
255. Narendra, D. P.; Jin, S. M.; Tanaka, A.; Suen, D. F.; Gautier, C. A.; Shen, J., et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 8:e1000298; 2010.
256. Matsuda, N.; Sato, S.; Shiba, K.; Okatsu, K.; Saisho, K.; Gautier, C. A., et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol 18 9 : 211-221; 2010.
257. Ruan, Q.; Harrington, A. J.; Caldwell, K. A.; Caldwell, G. A.; Standaert, D. G. VPS41, a protein involved in lysosomal trafficking, is protective in Caenor-habditis elegans and mammalian cellular models of Parkinson's disease. Neurobiol. Dis 37: 330-338; 2010.
258. Deng, H.; Dodson, M. W.; Huang, H.; Guo, M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc. Natl. Acad. Sci. USA 105: 14503-14508; 2008.
259. Poole, A. C.; Thomas, R. E.; Andrews, L. A.; McBride, H. M.; Whitworth, A. J.; Pallanck, L. J. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl. Acad. Sci. USA 105: 1638-1643; 2008. (Pubitemid 351346567)
260. Grunewald, A.; Gegg, M. E.; Taanman, J. W.; King, R. H.; Kock, N.; Klein, C., et al. Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. Exp. Neurol. 219: 266-273; 2009.
261. Mortiboys, H.; Thomas, K. J.; Koopman, W. J.; Klaffke, S.; Abou-Sleiman, P.; Olpin, S., et al. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann. Neurol 64: 555-565; 2008.
262. Piccoli, C.; Sardanelli, A.; Scrima, R.; Ripoli, M.; Quarato, G.; D'Aprile, A., et al. Mitochondrial respiratory dysfunction in familiar parkinsonism associated with PINK1 mutation. Neurochem. Res 33: 2565-2574; 2008.
263. Moore, D. J.; Zhang, L.; Dawson, T. M.; Dawson, V. L. A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J. Neurochem 87: 15 5 8 -1567; 2003. (Pubitemid 38020589)
264. Zhang, L.; Shimoji, M.; Thomas, B.; Moore, D. J.; Yu, S. W.; Marupudi, N. I., et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet 14: 2063-2073; 2005. (Pubitemid 41418042)
265. Nagakubo, D.; Taira, T.; Kitaura, H.; Ikeda, M.; Tamai, K.; Iguchi-Ariga, S. M., et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem. Biophys. Res. Commun 231: 509-513; 1997. (Pubitemid 27214343)
266. Abou-Sleiman, P. M.; Healy, D. G.; Quinn, N.; Lees, A. J.; Wood, N. W. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann. Neurol. 54: 283-286; 2003. (Pubitemid 37072030)
267. Canet-Aviles, R. M.; Wilson, M. A.; Miller, D. W.; Ahmad, R.; McLendon, C.; Bandyopadhyay, S., et al. The Parkinson's disease protein DJ-1 is neuropro-tective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. USA 101: 9103-9108; 2004. (Pubitemid 38781618)
268. Moore, D. J.; Zhang, L.; Troncoso, J.; Lee, M. K.; Hattori, N.; Mizuno, Y., et al. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet 14: 71-84; 2005. (Pubitemid 40123464)
269. Bonifati, V.; Rizzu, P.; Squitieri, F.; Krieger, E.; Vanacore, N.; van Swieten, J. C., et al. DJ-1 (PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol. Sci. 24: 15 9-160; 2003. (Pubitemid 37304291)
270. Taira, T.; Saito, Y.; Niki, T.; Iguchi-Ariga, S. M.; Takahashi, K.; Ariga, H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5: 213-218; 2004. (Pubitemid 38401204)
271. Hering, R.; Strauss, K. M.; Tao, X.; Bauer, A.; Woitalla, D.; Mietz, E. M., et al. Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum. Mutat. 24: 321-329; 2004. (Pubitemid 39336638)
272. Lev, N.; Ickowicz, D.; Melamed, E.; Offen, D. Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotox-icology 29: 397-405; 2008.
273. Meulener, M.; Whitworth, A. J.; Armstrong-Gold, C. E.; Rizzu, P.; Heutink, P.; Wes, P. D., et al. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr. Biol 15: 1572-1577; 20 05. (Pubitemid 41219597)
274. Park, J.; Kim, S. Y.; Cha, G. H.; Lee, S. B.; Kim, S.; Chung, J. Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. Gene 361: 133-139; 2005. (Pubitemid 41506941)
275. Meulener, M. C.; Xu, K.; Thomson, L.; Ischiropoulos, H.; Bonini, N. M. Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc. Natl. Acad. Sci. USA 10 3 : 12517-12522; 2006. (Pubitemid 44267290)
276. Kim, R. H.; Smith, P. D.; Aleyasin, H.; Hayley, S.; Mount, M. P.; Pownall, S., et al. Hypersensitivity of DJ-1-deficient mice to 1-"methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. USA 102: 5215-5220; 2005.
277. Martinat, C.; Shendelman, S.; Jonason, A.; Leete, T.; Beal, M. F.; Yang, L., et al. Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES-derived cell model of primary parkinsonism. PLoS Biol. 2:e327; 2004.
278. Shendelman, S.; Jonason, A.; Martinat, C.; Leete, T.; Abeliovich, A. DJ-1 is a redox-dependent molecular chaperone that inhibits a-synuclein aggregate formation. PLoS Biol. 2:e362; 2004.
279. Yang, W.; Chen, L.; Ding, Y.; Zhuang, X.; Kang, U. J. Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Hum. Mol. Genet 16: 2900-2910; 2007. (Pubitemid 350048387)
280. Im, J. Y.; Lee, K. W.; Junn, E.; Mouradian, M. M. DJ-1 protects against oxidative damage by regulating the thioredoxin/ASK1 complex. Neurosci. Res 67: 203-208; 2010.
281. Hayashi, T.; Ishimori, C.; Takahashi-Niki, K.; Taira, T.; Kim, Y. C.; Maita, H., et al. DJ-1 binds to mitochondrial complex I and maintains its activity. Biochem. Biophys. Res. Commun. 390: 667-672; 2009.
282. Krebiehl, G.; Ruckerbauer, S.; Burbulla, L. F.; Kieper, N.; Maurer, B.; Waak, J., et al. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS One 5:e9367; 2010.
283. Cunha-Oliveira, T.; Rego, A. C.; Oliveira, C. R. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res. Rev 58: 192-208; 2008.
284. San Luciano, M.; Saunders-Pullman, R. Substance abuse and movement disorders. Curr. Drug Abuse Rev 2: 273-278; 2009.
285. Brust, J. C. Substance abuse and movement disorders. Mov. Disord 25: 2010-2020; 2010.
286. Callaghan, R. C.; Cunningham, J. K.; Sykes, J.; Kish, S. J. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 120: 35-40; 2012.
287. Sulzer, D. How addictive drugs disrupt presynaptic dopamine neurotrans-mission. Neuron 69: 628-649; 2011.
288. Carvalho, M.; Carmo, H.; Costa, V. M.; Capela, J. P.; Pontes, H.; Remiao, F., et al. Toxicity of amphetamines: an update. Arch. Toxicol. 86: 11 6 7 -1231; 2012.
289. Sitte, H. H.; Huck, S.; Reither, H.; Boehm, S.; Singer, E. A.; Pifl, C. Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J. Neurochem 71: 1289-1297; 1998. (Pubitemid 28390284)
290. Jones, S. R.; Joseph, J. D.; Barak, L. S.; Caron, M. G.; Wightman, R. M. Dopamine neuronal transport kinetics and effects of amphetamine. J. Neurochem. 73: 2406-2414; 1999.
291. Sulzer, D.; Chen, T. K.; Lau, Y. Y.; Kristensen, H.; Rayport, S.; Ewing, A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci 15: 4102-4108; 1995.
292. Kahlig, K. M.; Binda, F.; Khoshbouei, H.; Blakely, R. D.; McMahon, D. G.; Javitch, J. A., et al. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc. Natl. Acad. Sci. USA 102 : 3495-3500; 2005. (Pubitemid 40328073)
293. Sulzer, D.; Sonders, M. S.; Poulsen, N. W.; Galli, A. Mechanisms of neuro-transmitter release by amphetamines: a review. Prog. Neurobiol. 75: 406-433; 2005. (Pubitemid 40834286)
294. Ramsay, R. R.; Hunter, D. J. Inhibitors alter the spectrum and redox properties of monoamine oxidase. A. Biochim. Biophys. Acta 178-184: 2002; 1601.
295. Ellison, G.; Eison, M. S.; Huberman, H. S.; Daniel, F. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science 201: 276-278; 1978. (Pubitemid 8396757)
296. Cunha-Oliveira, T.; Rego, A. C.; Morgadinho, M. T.; Macedo, T.; Oliveira, C. R. Differential cytotoxic responses of PC12 cells chronically exposed to psy-chostimulants or to hydrogen peroxide. Toxicology 217: 54-62; 2006. (Pubitemid 41758393)
297. Guilarte, T. R. Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology 22: 725-731; 2001. (Pubitemid 34075630)
298. Kobayashi, H.; Ide, S.; Hasegawa, J.; Ujike, H.; Sekine, Y.; Ozaki, N., et al. Study of association between a-synuclein gene polymorphism and methamphetamine psychosis/dependence. Ann. N. Y. Acad. Sci. 10 25: 325-334; 2004. (Pubitemid 39643878)
299. Fornai, F.; Lenzi, P.; Gesi, M.; Ferrucci, M.; Lazzeri, G.; Capobianco, L., et al. Similarities between methamphetamine toxicity and proteasome inhibition. Ann. N. Y. Acad. Sci. 1025: 162-170; 2004. (Pubitemid 39643859)
300. Iacovelli, L.; Fulceri, F.; De, B. A.; Nicoletti, F.; Ruggieri, S.; Fornai, F. The neurotoxicity of amphetamines: bridging drugs of abuse and neurodegen-erative disorders. Exp. Neurol. 201: 24-31; 2006. (Pubitemid 44223465)
301. Sherer, T. B.; Kim, J. H.; Betarbet, R.; Greenamyre, J. T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and a-synuclein aggregation. Exp. Neurol 179: 9-16; 20 03. (Pubitemid 36062614)
302. Fornai, F.; Schluter, O. M.; Lenzi, P.; Gesi, M.; Ruffoli, R.; Ferrucci, M., et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and a-synuclein. Proc. Natl. Acad. Sci. USA 102: 3413-3418; 2005. (Pubitemid 40328059)
303. Fornai, F.; Lenzi, P.; Ferrucci, M.; Lazzeri, G.; di Poggio, A. B.; Natale, G., et al. Occurrence of neuronal inclusions combined with increased nigral expression of a-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res. Bull 65: 405-413; 2005.
304. Vila, M.; Vukosavic, S.; Jackson-Lewis, V.; Neystat, M.; Jakowec, M.; Przedborski, S. a-Synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neu-rochem 74: 721-729; 2000. (Pubitemid 30053745)
305. Jung, B. D.; Shin, E. J.; Nguyen, X. K.; Jin, C. H.; Bach, J. H.; Park, S. J., et al. Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysac-charide administration. Neurochem. Int. 56: 229-244; 2010.
306. Yamamoto, B. K.; Bankson, M. G. Amphetamine neurotoxicity: cause and consequence of oxidative stress. Crit. Rev. Neurobiol. 17: 87-117; 2005. (Pubitemid 44174002)
307. Cadet, J. L.; Krasnova, I. N.; Jayanthi, S.; Lyles, J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox. Res. 11 : 183-202; 2007.
308. Wu, C. W.; Ping, Y. H.; Yen, J. C.; Chang, C. Y.; Wang, S. F.; Yeh, C. L., et al. Enhanced oxidative stress and aberrant mitochondrial biogenesis in human neuroblastoma SH-SY5Y cells during methamphetamine induced apoptosis. Toxicol. Appl. Pharmacol. 220: 243-251; 2007.
309. Pubill, D.; Chipana, C.; Camins, A.; Pallas, M.; Camarasa, J.; Escubedo, E. Free radical production induced by methamphetamine in rat striatal synapto-somes. Toxicol. Appl. Pharmacol 204: 57-68; 2005. (Pubitemid 40387567)
310. Frey, B. N.; Valvassori, S. S.; Gomes, K. M.; Martins, M. R.; Dal-Pizzol, F.; Kapczinski, F., et al. Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res. 1097: 224-229; 2006. (Pubitemid 44041287)
311. Jimenez, A.; Jorda, E. G.; Verdaguer, E.; Pubill, D.; Sureda, F. X.; Canudas, A. M., et al. Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells. Toxicol. Appl. Pharmacol 19 6 : 223-234; 2004. (Pubitemid 38469956)
312. Mirecki, A.; Fitzmaurice, P.; Ang, L.; Kalasinsky, K. S.; Peretti, F. J.; Aiken, S. S., et al. Brain antioxidant systems in human methamphetamine users. J. Neurochem. 89: 13 9 6 -1408; 2004. (Pubitemid 38802661)
313. Acikgoz, O.; Gonenc, S.; Kayatekin, B. M.; Pekcetin, C.; Uysal, N.; Dayi, A., et al. The effects of single dose of methamphetamine on lipid peroxidation levels in the rat striatum and prefrontal cortex. Eur. Neuropsychopharmacol 10: 415-418; 2000.
314. Frey, B. N.; Valvassori, S. S.; Reus, G. Z.; Martins, M. R.; Petronilho, F. C.; Bardini, K., et al. Changes in antioxidant defense enzymes after D-amphetamine exposure: implications as an animal model of mania. Neurochem. Res. 31: 699-703; 2006. (Pubitemid 43886419)
315. Carvalho, F.; Fernandes, E.; Remiao, F.; Gomes-Da-Silva, J.; Tavares, M. A.; Bastos, M. D. Adaptative response of antioxidant enzymes in different areas of rat brain after repeated D-amphetamine administration. Addict. Biol 6: 213-221; 2001. (Pubitemid 32675402)
316. Fitzmaurice, P. S.; Tong, J.; Yazdanpanah, M.; Liu, P. P.; Kalasinsky, K. S.; Kish, S. J. Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J. Pharmacol. Exp. Ther 319: 703-709; 2006.
317. Cunha-Oliveira, T.; Rego, A. C.; Morgadinho, M. T.; Macedo, T.; Oliveira, C. R. Differential cytotoxic responses of PC12 cells chronically exposed to psychostimulants or to hydrogen peroxide. Toxicology 217: 54-62; 2006. (Pubitemid 41758393)
318. El Avadi, A.; Zigmond, M. J. Low concentrations of methamphetamine can protect dopaminergic cells against a larger oxidative stress injury: mechanistic study. PLoS One 6:e24722; 2011.)